title: Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.
abstract: Fracture risk is higher in older adults with type 2 diabetes and may be influenced by treatments for diabetes. Oral anti-diabetic drugs have different effects on bone metabolism. The purpose of this review is to describe the effects of these drugs on bone metabolism and fracture risk. Osteoporosis is a progressive skeletal disorder that is characterized by compromised bone strength and increased risk of fracture. This condition has become an important global health problem, affecting approximately 200 million people worldwide. Another chronic and highly prevalent condition is diabetes mellitus, which affects more than 380 million people; both type 1 and type 2 diabetes are risk factors for fracture. Type 2 diabetes, in particular, is associated with impaired bone strength, although it is characterized by normal or elevated bone mineral density. Several therapeutic strategies are available to achieve the best outcomes in the management of diabetes mellitus but these have different effects on bone metabolism. The purpose of this narrative review is to describe the effects of oral hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-dependent glucose transporter 2 inhibitors) on bone metabolism and on the risk of developing fragility fractures in patients with type 2 diabetes. Both diabetes and osteoporosis represent a significant burden in terms of healthcare costs and quality of life. It is very important to choose therapies for diabetes that ensure good metabolic control whilst preserving skeletal health.
authors.affiliation: Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Via Alvaro del Portillo, 21-00128, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Palermo
authors.forename: L
authors.initials: L
authors.lastname: D'Onofrio
authors.forename: R
authors.initials: R
authors.lastname: Eastell
authors.forename: A V
authors.initials: AV
authors.lastname: Schwartz
authors.forename: P
authors.initials: P
authors.lastname: Pozzilli
authors.forename: N
authors.initials: N
authors.lastname: Napoli
mesh_terms: D000284:Administration, Oral; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D058866:Osteoporotic Fractures / Q000139:chemically induced* / Q000209:etiology; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents